Uncertainties in the PET defined A-/T+ subtype.
作者信息
Mormino Elizabeth C, Insel Philip S
机构信息
Department of Neurology and Neurological Sciences, Stanford Palo Alto California USA.
Wu Tsai Neuroscience Institute, Stanford Palo Alto California USA.
出版信息
Alzheimers Dement (Amst). 2022 Aug 26;14(1):e12348. doi: 10.1002/dad2.12348. eCollection 2022.
Abstract
摘要
相似文献
1
Uncertainties in the PET defined A-/T+ subtype.正电子发射断层扫描（PET）定义的A-/T+亚型中的不确定性。
Alzheimers Dement (Amst). 2022 Aug 26;14(1):e12348. doi: 10.1002/dad2.12348. eCollection 2022.
2
Effect of uncertainties in quantitative F-FDG PET/CT imaging feedback for intratumoral dose-response assessment and dose painting by number.定量F-FDG PET/CT成像反馈中的不确定性对瘤内剂量反应评估及按数字进行剂量描绘的影响。
Med Phys. 2020 Nov;47(11):5681-5692. doi: 10.1002/mp.14482. Epub 2020 Oct 17.
3
Mapping F-FDG Kinetics Together with Patient-Specific Bootstrap Assessment of Uncertainties: An Illustration with Data from a PET/CT Scanner with a Long Axial Field of View.同时绘制 F-FDG 动力学和基于患者的不确定性自举评估图谱：具有长轴向视野的 PET/CT 扫描仪数据的例证。
J Nucl Med. 2024 Jun 3;65(6):971-979. doi: 10.2967/jnumed.123.266686.
4
Spatial-temporal dynamic evolution of lewy body dementia by metabolic PET imaging.通过代谢正电子发射断层扫描成像研究路易体痴呆的时空动态演变。
Eur J Nucl Med Mol Imaging. 2024 Dec;52(1):145-157. doi: 10.1007/s00259-024-06881-w. Epub 2024 Aug 19.
5
The impact of uncertainties in the CT conversion algorithm when predicting proton beam ranges in patients from dose and PET-activity distributions.当根据剂量和 PET 活性分布预测质子束在患者中的射程时，CT 转换算法中的不确定性的影响。
Phys Med Biol. 2010 Dec 21;55(24):7557-71. doi: 10.1088/0031-9155/55/24/011. Epub 2010 Nov 19.
6
Characterization of positioning uncertainties in PET-CT-MR trimodality solutions for radiotherapy.在用于放射治疗的 PET-CT-MR 三联体解决方案中定位不确定性的特性描述。
J Appl Clin Med Phys. 2022 Jul;23(7):e13617. doi: 10.1002/acm2.13617. Epub 2022 Apr 28.
7
The relationship between FDG PET/CT-defined metabolic parameters and the histopathological subtype of oesophageal carcinomas.氟代脱氧葡萄糖正电子发射断层扫描/计算机断层扫描（FDG PET/CT）定义的代谢参数与食管癌组织病理学亚型之间的关系。
Pol J Radiol. 2020 May 15;85:e254-e260. doi: 10.5114/pjr.2020.95945. eCollection 2020.
8
Molecular subtype classification of breast cancer using established radiomic signature models based on F-FDG PET/CT images.基于 F-FDG PET/CT 图像的放射组学特征模型对乳腺癌进行分子亚型分类。
Front Biosci (Landmark Ed). 2021 Aug 30;26(9):475-484. doi: 10.52586/4960.
9
Mitigating SUV uncertainties using total body PET imaging.使用全身正电子发射断层扫描技术减轻 SUV 不确定性。
Eur J Nucl Med Mol Imaging. 2024 Mar;51(4):1070-1078. doi: 10.1007/s00259-023-06503-x. Epub 2023 Nov 13.
10
Monte Carlo-based lung cancer treatment planning incorporating PET-defined target volumes.
J Appl Clin Med Phys. 2005 Fall;6(4):65-76. doi: 10.1120/jacmp.v6i4.2156. Epub 2005 Nov 21.
本文引用的文献
1
Exploring discordant low amyloid beta and high neocortical tau positron emission tomography cases.探索淀粉样β蛋白水平低而新皮质tau蛋白正电子发射断层扫描水平高的不一致病例。
Alzheimers Dement (Amst). 2022 Aug 26;14(1):e12326. doi: 10.1002/dad2.12326. eCollection 2022.
2
Plasma p217+tau versus NAV4694 amyloid and MK6240 tau PET across the Alzheimer's continuum.阿尔茨海默病连续体中血浆p217 + tau与NAV4694淀粉样蛋白及MK6240 tau正电子发射断层扫描的对比
Alzheimers Dement (Amst). 2022 Apr 5;14(1):e12307. doi: 10.1002/dad2.12307. eCollection 2022.
3
Variant-dependent heterogeneity in amyloid β burden in autosomal dominant Alzheimer's disease: cross-sectional and longitudinal analyses of an observational study.常染色体显性阿尔茨海默病淀粉样β负担的变异依赖性异质性：一项观察性研究的横断面和纵向分析。
Lancet Neurol. 2022 Feb;21(2):140-152. doi: 10.1016/S1474-4422(21)00375-6.
4
Plasma phosphorylated tau 217 and phosphorylated tau 181 as biomarkers in Alzheimer's disease and frontotemporal lobar degeneration: a retrospective diagnostic performance study.血浆磷酸化 tau 217 和磷酸化 tau 181 作为阿尔茨海默病和额颞叶变性的生物标志物：一项回顾性诊断性能研究。
Lancet Neurol. 2021 Sep;20(9):739-752. doi: 10.1016/S1474-4422(21)00214-3.
5
Temporal Dynamics of β-Amyloid Accumulation in Aging and Alzheimer Disease.β-淀粉样蛋白在衰老和阿尔茨海默病中的积累的时间动态。
Neurology. 2021 Mar 2;96(9):e1347-e1357. doi: 10.1212/WNL.0000000000011524. Epub 2021 Jan 6.
6
Centiloid cut-off values for optimal agreement between PET and CSF core AD biomarkers.PET 和 CSF 核心 AD 生物标志物之间最佳一致性的百分位截断值。
Alzheimers Res Ther. 2019 Mar 21;11(1):27. doi: 10.1186/s13195-019-0478-z.
7
Multisite study of the relationships between antemortem [C]PIB-PET Centiloid values and postmortem measures of Alzheimer's disease neuropathology.多中心研究生前 [C]PIB-PET 百分位值与阿尔茨海默病神经病理学死后测量值之间的关系。
Alzheimers Dement. 2019 Feb;15(2):205-216. doi: 10.1016/j.jalz.2018.09.001. Epub 2018 Oct 19.
8
NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease.NIA-AA 研究框架：迈向阿尔茨海默病的生物学定义。
Alzheimers Dement. 2018 Apr;14(4):535-562. doi: 10.1016/j.jalz.2018.02.018.
9
High performance plasma amyloid-β biomarkers for Alzheimer's disease.用于阿尔茨海默病的高性能血浆淀粉样蛋白-β生物标志物。
Nature. 2018 Feb 8;554(7691):249-254. doi: 10.1038/nature25456. Epub 2018 Jan 31.
10
Flortaucipir tau PET imaging in semantic variant primary progressive aphasia.Flortaucipir tau PET 成像在语义变异型原发性进行性失语症中的应用。
J Neurol Neurosurg Psychiatry. 2018 Oct;89(10):1024-1031. doi: 10.1136/jnnp-2017-316409. Epub 2017 Oct 6.
Zotero 插件